More New EU Drug Approvals Bring Total For Year To 14
Executive Summary
Seven new drugs were approved in the EU in the March-April period this year: TiGenix/Takeda's Alofisel, BioCryst's Alpivab, Chiesi's Lamzede, AstraZeneca's Lokelma, Pfizer's Mylotarg, GSK's Shingrix and MSD's Steglatro.
You may also be interested in...
Sun Rises For GSK's Trelegy And Shingrix While It Sets For Advair
The drug maker is in the midst of launching several new drugs, including the Shingrix vaccine, the triple COPD therapy Trelegy and the HIV regimen Juluca, hoping new drugs will drive growth as Advair sunsets.
EU Yes For TiGenix Marks Tenth ATMP Approval in Ten Years
TiGenix says its treatment for complex perianal fistulae in Crohn’s disease is the first allogeneic stem cell therapy to be approved under Europe’s centralized marketing authorization pathway.
Seven New Drugs Approved In EU In First Two Months of 2018
Seven products containing a new active substance were approved in Europe in the first two months of 2018: Shire's Adynovi and Roche/Chugai's Hemlibra for hemophilia A, Roche's Ocrevus for multiple sclerosis, Kyowa Kirin's Crysvita for hypophosphatemia, AstraZeneca's Fasenra for asthma, Novo Nordisk's Ozempic for diabetes, and MSD's Prevymis for prophylaxis of cytomegalovirus infection.